Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Income towards Parent Company: 2013-2025

Historic Income towards Parent Company for Coherus Oncology (CHRS) over the last 12 years, with Sep 2025 value amounting to $9.0 million.

  • Coherus Oncology's Income towards Parent Company fell 75.61% to $9.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $540.3 million, marking a year-over-year increase of 217.73%. This contributed to the annual value of $28.5 million for FY2024, which is 111.98% up from last year.
  • Per Coherus Oncology's latest filing, its Income towards Parent Company stood at $9.0 million for Q3 2025, which was down 97.38% from $342.6 million recorded in Q2 2025.
  • Coherus Oncology's Income towards Parent Company's 5-year high stood at $342.6 million during Q2 2025, with a 5-year trough of -$172.9 million in Q1 2021.
  • Moreover, its 3-year median value for Income towards Parent Company was $9.0 million (2025), whereas its average is $50.2 million.
  • As far as peak fluctuations go, Coherus Oncology's Income towards Parent Company crashed by 586.19% in 2021, and later skyrocketed by 717.15% in 2025.
  • Coherus Oncology's Income towards Parent Company (Quarterly) stood at -$45.7 million in 2021, then fell by 28.75% to -$58.9 million in 2022, then plummeted by 35.30% to -$79.7 million in 2023, then skyrocketed by 348.34% to $197.8 million in 2024, then slumped by 75.61% to $9.0 million in 2025.
  • Its Income towards Parent Company was $9.0 million in Q3 2025, compared to $342.6 million in Q2 2025 and -$9.2 million in Q1 2025.